Heart injection trial for chest pain withdrawn before starting
NCT ID NCT01002495
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study aimed to test the safety of injecting a gene therapy called VM202 directly into the heart muscle of people with severe, untreatable chest pain due to blocked arteries. The trial was withdrawn before enrolling any participants, so no results are available. The goal was to see if VM202 could help grow new blood vessels and improve blood flow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL ISCHEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407, United States
-
Northwestern Memorial Hospital
Chicago, Illinois, United States
Conditions
Explore the condition pages connected to this study.